Abstract
The objective of this study was to compare the effects of a β3-adrenoceptor (β3-AR) agonist on bladder function and cardiovascular parameters in rats with those of several drugs that act on smooth muscle. CL316,243 (β3-AR agonist), isoproterenol (nonselective β-AR agonist), procaterol (β2-AR agonist), verapamil (Ca2+ antagonist), and papaverine (antispastic drug) each evoked a concentration-dependent relaxation of the detrusor in vitro. They also reduced bladder pressure in anesthetized rats, the β-AR agonists apparently being more potent than the other drugs. Atropine (muscarinic antagonist) neither relaxed detrusor strips nor reduced bladder pressure. In anesthetized rats, CL316,243 and atropine each had only a slight influence on blood pressure and heart rate, but isoproterenol, procaterol, verapamil, and papaverine significantly affected cardiovascular function at the same dose range as that required to reduce bladder pressure. In cystometry experiments, CL316,243 (10 μg/kg i.v.), verapamil (1 mg/kg i.v.), and papaverine (1 mg/kg i.v.) all significantly prolonged micturition interval and increased bladder capacity, but did not change the residual urine volume after a micturition contraction. Procaterol (100 μg/kg i.v.) prolonged the micturition interval and increased both bladder capacity and residual urine volume (all significantly). Atropine (100 μg/kg i.v.) reduced micturition pressure and increased residual urine volume (both significantly). Because the human detrusor, like the rat detrusor, relaxes on β3-AR stimulation, we conclude that this β3-AR agonist may have potential in pollakiuria (frequent urination) as a therapeutic agent without cardiovascular side effects.
Footnotes
-
Send reprint requests to: Hiroo Takeda, Central Research Laboratory, Kissei Pharmaceutical Co. Ltd., 4365-1, Hotaka, Nagano-Pref., 399-8304, Japan. E-mail:hiroo_takeda{at}pharm.kissei.co.jp
-
↵1 Part of this investigation was presented at the 1st International Consultation on Incontinence (Takeda H. et al., June 28, 1998) and at the XIIIth International Congress of Pharmacology (Takeda H. et al., July 26, 1998).
- Abbreviations:
- β-AR
- β-adrenoceptor
- CL316,243
- (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethylamino]propyl]-1,3-benzodioxole-2,2-dicarboxylate
- Received December 13, 1999.
- Accepted February 14, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|